JP2023516028A5 - - Google Patents

Info

Publication number
JP2023516028A5
JP2023516028A5 JP2022552175A JP2022552175A JP2023516028A5 JP 2023516028 A5 JP2023516028 A5 JP 2023516028A5 JP 2022552175 A JP2022552175 A JP 2022552175A JP 2022552175 A JP2022552175 A JP 2022552175A JP 2023516028 A5 JP2023516028 A5 JP 2023516028A5
Authority
JP
Japan
Prior art keywords
sequence
cdr sequence
cdr1
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516028A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/020291 external-priority patent/WO2021174198A1/en
Publication of JP2023516028A publication Critical patent/JP2023516028A/ja
Publication of JP2023516028A5 publication Critical patent/JP2023516028A5/ja
Pending legal-status Critical Current

Links

JP2022552175A 2020-02-28 2021-03-01 多重特異性抗体を介したトランスフォーミング増殖因子ベータスーパーファミリーシグナル伝達の選択的調節 Pending JP2023516028A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062983374P 2020-02-28 2020-02-28
US62/983,374 2020-02-28
PCT/US2021/020291 WO2021174198A1 (en) 2020-02-28 2021-03-01 Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies

Publications (2)

Publication Number Publication Date
JP2023516028A JP2023516028A (ja) 2023-04-17
JP2023516028A5 true JP2023516028A5 (enExample) 2024-03-12

Family

ID=77491585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552175A Pending JP2023516028A (ja) 2020-02-28 2021-03-01 多重特異性抗体を介したトランスフォーミング増殖因子ベータスーパーファミリーシグナル伝達の選択的調節

Country Status (9)

Country Link
US (1) US20230220085A1 (enExample)
EP (2) EP4110389A4 (enExample)
JP (1) JP2023516028A (enExample)
KR (1) KR20220160584A (enExample)
CN (1) CN115515632A (enExample)
AU (1) AU2021228778A1 (enExample)
CA (1) CA3173521A1 (enExample)
IL (1) IL295980A (enExample)
WO (1) WO2021174198A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12409219B2 (en) 2020-06-30 2025-09-09 Boost Biopharma, Inc. Recombinant polypeptides containing at least one immunogenic fragment and uses thereof
TW202328190A (zh) * 2021-09-03 2023-07-16 大陸商來凱醫藥科技(上海)有限公司 抗acvr2a抗體及其用途
US20250109173A1 (en) * 2021-12-31 2025-04-03 Boost Biopharma, Inc. Recombinant polypeptides containing at least one immunogenic fragment and antibody fc region and uses thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024086754A2 (en) * 2022-10-19 2024-04-25 Tentarix Biotherapeutics, Inc. Multi variable domain therapeutic immunoglobulin
US20250002588A1 (en) 2023-04-07 2025-01-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025027052A1 (en) 2023-07-31 2025-02-06 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
WO2025026353A1 (en) * 2023-08-01 2025-02-06 Laekna Therapeutics Shanghai Co., Ltd. Anti-acvr2b antibodies and uses thereof
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2026013184A1 (en) 2024-07-10 2026-01-15 Ac Immune Sa Fusion protein peptide linkers and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
ES2113371T3 (es) 1989-11-16 1998-05-01 Univ Duke Transformacion de celulas epidermicas de tejidos animales con la ayuda de particulas.
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
AU737155B2 (en) 1997-03-14 2001-08-09 Biogen Idec Inc. Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
AU2001297872B2 (en) 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
NZ527283A (en) 2001-01-29 2006-03-31 Biogen Idec Inc Modified antibodies and methods of use
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2662350A1 (en) * 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
EP3124497B1 (en) * 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
WO2011116212A2 (en) * 2010-03-17 2011-09-22 Oncomed Pharmaceuticals, Inc. Bone morphogenetic protein receptor binding agents and methods of their use
US20120201746A1 (en) * 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
MX2013011363A (es) * 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
US20170218091A1 (en) * 2014-07-03 2017-08-03 Abbvie Inc. Monovalent binding proteins
TWI703156B (zh) * 2015-01-30 2020-09-01 學校法人埼玉醫科大學 抗alk2抗體
KR20180002653A (ko) * 2015-04-07 2018-01-08 제넨테크, 인크. 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
CA3052625A1 (en) * 2017-02-06 2018-08-09 Acceleron Pharma Inc. Compositions and methods for treating heart failure
AU2018358804A1 (en) * 2017-11-02 2020-04-09 Bayer Aktiengesellschaft Bispecific antibodies binding ALK-1 and BMPR-2

Similar Documents

Publication Publication Date Title
JP2023516028A5 (enExample)
JP2021525546A5 (enExample)
JP2024175003A5 (enExample)
JP2021531826A5 (enExample)
CN115461364A (zh) 一种抗新型冠状病毒的单克隆抗体及其应用
JP2022545196A5 (enExample)
JP2023503846A5 (enExample)
RU2014151788A (ru) Молекула, специфически связывающаяся с rsv
JP2009517057A5 (enExample)
JP2023078174A5 (enExample)
JP2010514835A5 (enExample)
JP2018532766A5 (enExample)
RU2012157042A (ru) СПОСОБ ИНГИБИРОВАНИЯ GM-CSFRα У ПАЦИЕНТА
JP2022545647A5 (enExample)
JP2012526530A (ja) ヒト化axl抗体
RU2008146922A (ru) Антитела, связывающиеся с внеклеточным доменом тирозинкиназного рецептора (alk)
JP2009535021A5 (enExample)
JP2023549537A5 (enExample)
JP2023525495A5 (enExample)
JP2014534218A5 (enExample)
JP2023519776A5 (enExample)
JP2020500834A5 (enExample)
JP2023509390A5 (enExample)
JP2020530285A5 (enExample)
JP2018514193A5 (enExample)